600 patients66,869 observations120 daysLIVE

Patient P-01884

Synthetic patientNBL-101 · Day 108 · 55–64 · M · baseline S19Open companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
53%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S19
  2. Day 12 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 14 GI-04 recommendedGI Support Protocol GI-04
  4. Day 15 Patient acceptedStarted GI-04 in the companion
  5. Day 23 No meaningful changeGI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 12.

Primary contributors, last 14 days
  • GI instability+29
  • Inflammatory activity+20
  • Nutritional resilience-16
  • Treatment adherence+4
  • Toxicity-2

What helped?

  • GI Support Protocol GI-04Day 14
    Result: no meaningful change
LIFE OS recommendation
Clinician Review CR-01
72%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
  • Inflammatory signalling 35
    • MicrobiomeBacteroides fragilis expansion
    • WearableHRV 24 ms, trending down
  • Butyrate / short-chain fatty acid production 25
    • MicrobiomeF. prausnitzii depleted
  • Autonomic recovery 20
    • Wearable2,436 steps/day
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 46/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
33 ms
Sleep
6.3 h
Steps
3,490
Resting HR
66 bpm
Daily log: GI score 30, nutritional resilience 57, adherence 97.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0178753%S1951
P-0170149%S1155
P-0158548%S1349
P-0182348%S0157
P-0187147%S16HY-01no change57
P-0134246%S11DT-01improved48
P-0146144%S1961
P-0143043%S05CR-01improved54
P-0144643%S0353
P-0159343%S10HY-01improved56
P-0163143%S1459
P-0180443%S19AD-05improved61